MCF Advisors’s Novo Nordisk NVO Stock Holding History

MCF Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.9K	Sell	1,083 -2,094	-66%	-$90K	﹤0.01%	671
2026 Q1	$121K	Buy	3,177 +3,127	+6,254%	+$148K	0.01%	472
2025 Q4	$2.54K	Sell	50 -705	-93%	-$36.1K	﹤0.01%	1035
2025 Q3	$41.9K	Hold	755	–	–	﹤0.01%	454
2025 Q2	$52.1K	Hold	755	–	–	﹤0.01%	396
2025 Q1	$52.4K	Hold	755	–	–	﹤0.01%	390
2024 Q4	$64.9K	Hold	755	–	–	﹤0.01%	366
2024 Q3	$89.9K	Hold	755	–	–	0.01%	313
2024 Q2	$108K	Sell	755 -50	-6%	-$6.63K	0.01%	295
2024 Q1	$103K	Buy	805 +329	+69%	+$39.2K	0.01%	294
2023 Q4	$49.2K	Buy	476 +468	+5,850%	+$46.3K	﹤0.01%	370
2023 Q3	$728	Buy	+8	New	+$705	﹤0.01%	854
2016 Q4	–	Sell	-136	Closed	-$3K	–	459
2016 Q3	$3K	Sell	136 -154	-53%	-$3.82K	﹤0.01%	404
2016 Q2	$8K	Buy	+290	New	+$7.95K	﹤0.01%	367

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

MCF Advisors's NVO Position: Q2 2026 in Review

MCF Advisors reduced its Novo Nordisk (NVO) stake by 66% in Q2 2026, selling an estimated $90K and leaving 1,083 shares worth $51.9K. The position accounts for ﹤0.01% of the portfolio, ranked #671.

MCF Advisors first reported a position in NVO in Q2 2016 and has held it in 14 quarters since. The position peaked at $121K in Q1 2026. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

MCF Advisors held 1,083 shares of Novo Nordisk worth $51.9K as of Q2 2026.
MCF Advisors sold 2,094 Novo Nordisk shares in Q2 2026, an estimated $90K.
Novo Nordisk made up ﹤0.01% of MCF Advisors's portfolio in Q2 2026, its #671 holding.
MCF Advisors first reported a position in Novo Nordisk in Q2 2016 and has held it in 14 quarters since.
MCF Advisors's Novo Nordisk position peaked at $121K in Q1 2026.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on MCF Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.